Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Core Insights - Alterity Therapeutics announced positive results from the ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA) at the MSA Research Symposium [1][2] - The trial demonstrated significant clinical efficacy of ATH434, with a 48% relative treatment effect at the 50 mg dose and a 30% effect at the 75 mg dose [3][5] - ATH434 is designed to inhibit the aggregation of pathological proteins and has shown potential in treating neurodegenerative diseases [4][8] Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease and related disorders [8] - The company is based in Melbourne, Australia, and San Francisco, California, and is advancing its lead candidate, ATH434, through clinical trials [8] Clinical Trial Details - The ATH434-201 Phase 2 trial involved 77 patients and assessed the efficacy, safety, and pharmacokinetics of ATH434 over 12 months [5][6] - Key findings included a clinically significant reduction in disease severity on the modified UMSARS I scale and improvements in motor activities measured by wearable sensors [3][5] - ATH434 was well tolerated, with no serious adverse events reported, and showed trends in reducing iron accumulation in MSA-affected brain regions [3][4][6] Disease Context - Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease affecting the autonomic nervous system and movement [7] - MSA currently has no approved treatments that can slow disease progression, highlighting the potential impact of successful therapies like ATH434 [7]